MariMed Inc. Files 8-K for Financial Reporting
Ticker: MRMD · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1522767
| Field | Detail |
|---|---|
| Company | Marimed Inc. (MRMD) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, results-of-operations
Related Tickers: MRMD
TL;DR
MariMed dropped an 8-K on March 6th detailing financials. Check it for the latest numbers.
AI Summary
MariMed Inc. filed an 8-K on March 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing details the company's financial performance and provides supporting documentation for its reporting period ending March 6, 2024.
Why It Matters
This filing provides crucial updates on MariMed Inc.'s financial health and operational results, offering insights for investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- MARIMED INC. (company) — Registrant
- 0001522767-24-000005 (filing_id) — Accession Number
- March 6, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Norwood, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by MariMed Inc.?
The primary purpose of this 8-K filing is to report on MariMed Inc.'s Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
On what date was this 8-K filed?
This 8-K was filed on March 6, 2024.
What is MariMed Inc.'s principal executive office address?
MariMed Inc.'s principal executive office is located at 10 Oceana Way, Norwood, MA 02062.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is MariMed Inc.'s IRS Employer Identification Number?
MariMed Inc.'s IRS Employer Identification Number is 27-4672745.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-06 17:06:10
Filing Documents
- mrmd-20240306.htm (8-K) — 24KB
- marimedq42023ex991.htm (EX-99.1) — 301KB
- picture2.jpg (GRAPHIC) — 8KB
- 0001522767-24-000005.txt ( ) — 471KB
- mrmd-20240306.xsd (EX-101.SCH) — 2KB
- mrmd-20240306_lab.xml (EX-101.LAB) — 20KB
- mrmd-20240306_pre.xml (EX-101.PRE) — 11KB
- mrmd-20240306_htm.xml (XML) — 2KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 6, 2024, MariMed Inc. (the "Company") issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three months and year ended December 31, 2023.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 6, 2024, announcing financial results for the three months and year ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, furnished pursuant to Item 2.02, including Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. **********
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARIMED INC. Dated: March 6, 2024 By: /s/ Jon R. Levine Jon R. Levine President, Chief Executive Officer and Interim Chief Financial Officer